Medical Doctor Program year 2025 Reported 2019–2025 Source: CMS Open Payments, 2026 publication

Fabrizio Galimberti

MOHS-Micrographic Surgery Conway, SC Medical Doctor

NPI 1639531825 CMS profile 4218727

808 Farrar Dr, Conway, SC 29526

Open in the dashboard

General payments

$764,946

1,123 records reported · program years 2019–2025

Research payments

$0

Paid to them · None reported · program years 2019–2025

Ownership & investment interest

$0

None reported

Through program year 2025, Fabrizio Galimberti of Conway, SC is reported in the CMS Open Payments database as having received $764,946 across 1,123 general payments and $0 in research payments paid to them.

No combined total General, research and ownership are kept apart. Each is reported under its own rules, and ownership is not money that moved at all but the value of a stake held. A meal, a clinical trial grant and a shareholding do not add up to anything meaningful, so this site does not add them.

General payments for this record sit in the 99th percentile of MOHS-Micrographic Surgery profiles with reported payments. Percentile describes the distribution, not the conduct.

By program year

7 rows
Year Kind Relative to this record's peak year Amount Records
2025 General $484,408 565
2024 General $247,013 333
2023 General $26,562 152
2022 General $2,070 28
2021 General $1,330 15
2020 General $1,734 7
2019 General $1,829 23

Beside peers

Year by year, beside peers General payments · among profiles paid that year
  • Fabrizio Galimberti
  • MOHS-Micrographic Surgery median
  • Middle half of MOHS-Micrographic Surgery
  • National median

In program year 2025, general payments to Fabrizio Galimberti were reported at $484,408. Among 1,077 MOHS-Micrographic Surgery profiles paid that year, the median was $465 and the middle half received between $145 and $1,066.

Show as a table
Year Fabrizio Galimberti MOHS-Micrographic Surgery median Middle half National median
2019 $1,829 $316 $106–$785 $163
2020 $1,734 $162 $68–$412 $114
2021 $1,330 $243 $87–$654 $132
2022 $2,070 $300 $102–$887 $149
2023 $26,562 $364 $125–$1,010 $160
2024 $247,013 $445 $142–$1,108 $164
2025 $484,408 $465 $145–$1,066 $169

Breakdown

Who paid General payments · program years 2019–2025
  1. Janssen Biotech, Inc. $166,436 151 payments
  2. UCB, Inc. $117,033 160 payments
  3. Galderma Laboratories, L.P. $104,682 94 payments
  4. AbbVie, Inc. $87,816 105 payments
  5. Sun Pharmaceutical Industries Inc. $74,021 107 payments
  6. LEO Pharma Inc. $66,515 91 payments
  7. Arcutis Biotherapeutics, Inc. $33,877 58 payments
  8. E.R. Squibb & Sons, L.L.C. $30,443 54 payments
  9. Almirall LLC $24,407 24 payments
  10. Boehringer Ingelheim Pharmaceuticals, Inc. $22,122 20 payments
  11. Other $37,594 259 payments

Every payment, record by record

What the payments were for General payments · program years 2019–2025
  1. Compensation for services other than consulting, including serving as faculty or as a speaker at a venue other than a continuing education program $502,885 140 payments
  2. Consulting Fee $136,494 56 payments
  3. Travel and Lodging $79,295 192 payments
  4. Food and Beverage $34,613 722 payments
  5. Compensation for serving as faculty or as a speaker for a medical education program $11,164 3 payments
  6. Education $487 9 payments
  7. Honoraria $8 1 payment
Products named General payments · program years 2019–2025
  1. TREMFYA $166,945 155 payments
  2. Bimzelx $113,266 154 payments
  3. RINVOQ $85,865 80 payments
  4. NEMLUVIO $76,239 67 payments
  5. LEVULAN KERASTICK $60,156 36 payments
  6. ADBRY $47,287 70 payments
  7. Zoryve $33,714 52 payments
  8. Klisyri $24,407 24 payments
  9. ANZUPGO $23,349 22 payments
  10. SPEVIGO $22,122 20 payments
  11. Other $78,630 444 payments

A payment can name more than one product, so these amounts overlap and do not add up to the general-payment figure.

Prescribing to Medicare patients

Part D · data year 2024 · 35 drugs

Part D claims

2,232

Median for Dermatology: 534

Drug cost

$2,358,889

Median for Dermatology: $67,151

Branded share of claims

20.3%

Median for Dermatology: 8.1%

Drugs this doctor was counted under in Medicare Part D 2024, by drug cost
Drug Type Relative to their largest Claims Drug cost
Dupixent Pen Dupilumab Brand 129 $581,080
Tremfya Guselkumab Brand 27 $372,805
Bimzelx Autoinjector Bimekizumab-Bkzx Brand 24 $362,544
Skyrizi Pen Risankizumab-Rzaa Brand 11 $234,302
Odomzo Sonidegib Phosphate Brand 11 $154,397
Otezla Apremilast Brand 25 $123,165
Cosentyx Sensoready (2 Pens) Secukinumab Brand 13 $99,206
Nemluvio Nemolizumab-Ilto Brand 13 $88,051
Opzelura Ruxolitinib Phosphate Brand 41 $81,561
Adbry Tralokinumab-Ldrm Brand 14 $54,251

The 10 drugs with the highest cost, of 35 counted.

Drug cost is what was paid for the drugs at the pharmacy — by Medicare, the patient and others — and is not money to the prescriber. Medicare Part D only: drugs dispensed to Medicare beneficiaries. A drug with fewer than 11 claims for this prescriber is not published, so a missing drug does not mean zero. The medians are for the 13,550 Part D prescribers listed as Dermatology; they describe a distribution and say nothing about conduct.

Billing to Medicare

Part B · data year 2024 · 51 billing codes

Paid by Medicare

$97,069

Medicare's payments for the services billed

Medicare patients

683

Average age 73

Services billed

2,653

325 women, 358 men among their patients

Share of this provider's Medicare patients with each condition
Condition among their Medicare patients Relative to the most common Share of patients
High blood pressure 75%
Arthritis 48%
Diabetes 28%
Ischemic heart disease 26%
Atrial fibrillation 17%
COPD 16%
Chronic kidney disease 15%
Depression 15%

Medicare Part B only: services billed to Medicare. Rows covering fewer than 11 beneficiaries are not published. Only drugs given in the clinic are itemised here; the rest of what this provider billed is in the total above.

Payments and prescribing

First 5 of 26 products · payments 2024

Two separate records. The payments come from Open Payments and the claims from Medicare. They are set side by side because they name the same product; they do not show that a payment affected a prescription.

Products this doctor was paid in connection with in 2024, beside Medicare claims for the same product
Product Paid by Related payments Part D claims Part B services
TREMFYA
$80,586 27 —
RINVOQ
$41,647 — —
ADBRY
$26,501 14 —
LEVULAN KERASTICK
$20,309 — —
Bimzelx
$15,529 24 —

A dash means Medicare published no figure for this doctor and product — fewer than 11 claims, or the product is not covered under that part — which is not the same as none. Payments are general payments only; one that names several products is split evenly between them, so an amount is payments related to the product, not money paid for it.

See more in the dashboard: 25 with a free account, all 26 with Patron

Records

1,123 reported

Every payment, record by record

Date, company, amount, what it was for and the product named — filter by year, kind and company, or download as CSV.

Other MOHS-Micrographic Surgery in South Carolina

Related records

What this means

U.S. law requires drug and medical device manufacturers to report payments and transfers of value they make to physicians and teaching hospitals. The Centers for Medicare & Medicaid Services publishes that record each year. This page shows what was reported about this person, and nothing else.

An ownership interest is different from the other two. It is not a payment: it is a stake — shares, options, a partnership holding — that a physician or an immediate family member held in a manufacturer during that year. The figure shown is what the stake was reported to be worth.

Research payments frequently pass through a clinician to the institution running a trial, and rarely represent personal income. They should be read differently from general payments.

Provenance

Source: CMS Open Payments · through program year 2025

Data current to program year 2025, from CMS's 2026 publication.

We reproduce what manufacturers reported. We do not verify, edit or correct the underlying records.

A payment record is not evidence of wrongdoing. Financial relationships between industry and medicine are legal, common and often necessary for research. Who Paid My Doc reports what was disclosed; it does not judge it.

Who Paid My Doc is independent and is not affiliated with, endorsed by or sponsored by CMS or any U.S. government agency. It is not a consumer reporting agency and this is not a consumer report; do not use it for decisions covered by the Fair Credit Reporting Act.

How to dispute or correct a record